ATRS NASDAQ

Antares Pharma, Inc. operates as a specialized pharmaceutical enterprise, primarily dedicated to innovating and marketing medicines and advanced technologies. Its core mission is to address critical patient needs across a range of therapeutic areas. The company achieves this by developing, manufacturing, and commercializing groundbreaking therapeutic products, often leveraging its distinctive drug delivery systems. A significant portion of its product lineup involves injectable solutions. This includes XYOSTED, a subcutaneous therapy for testosterone replacement in adult men, and OTREXUP, an injectable methotrexate formulation used to manage severe active rheumatoid arthritis, active polyarticular juvenile idiopathic arthritis in children, and severe recalcitrant psoriasis in adults. While primarily known for its injectable portfolio, Antares also offers NOCDURNA sublingual tablets, prescribed for adults experiencing nocturia due to nocturnal polyuria, where they awaken multiple times nightly to urinate. Further expanding its therapeutic offerings, the company provides generic Epinephrine Injection USP for the urgent treatment of severe allergic reactions, including anaphylaxis, applicable to adults and certain pediatric patients. Other key products include Sumatriptan Injection USP for the acute management of migraine and cluster headaches in adults, and the Makena subcutaneous auto-injector, designed to lower the risk of preterm birth in women. Additionally, Antares markets Teriparatide injection for osteoporosis, addressing both postmenopausal women and men at heightened fracture risk, as well as those with glucocorticoid-induced osteoporosis. Beyond existing medications, Antares Pharma is actively involved in the development of various drug delivery devices, such as disposable pen injectors for diabetes and osteoporosis, and QuickShot auto-injectors. It is also advancing TLANDO for the treatment of testosterone deficiency in adult males, alongside other innovative drug/device combinations targeting urologic oncology, immunology, and endocrinology. The company has established strategic alliances and collaborative partnerships with prominent pharmaceutical entities like Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Founded in 1979 and headquartered in Ewing, New Jersey, Antares Pharma, Inc. transitioned into a subsidiary of Halozyme Therapeutics, Inc. as of May 23, 2022.